5 months ago
2
Aurobindo Pharma subsidiary CuraTeQ Biologics and U.S. steadfast BioFactura person terminated their statement relating to BFI-751, a projected biosimilar to Janssen Biotech’s Stelara (Ustekinumab).
The determination is aligned with CuraTeQ’s strategical portfolio prioritisation and not expected to person a worldly interaction connected the company’s wide biosimilars strategy, Aurobindo Pharma said successful a filing connected Saturday. Ustekinumab is simply a recombinant monoclonal antibody utilized for treating Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
As per their July 7, 2023 agreement, BioFactura was to person licence fees dispersed crossed antithetic milestones starring to commercialisation successful regulated markets and CuraTeQ the planetary manufacturing rights. CuraTeQ was to person 57 - 60% of the profits, from the biosimilar, depending upon the markets. In 2022, Stelara (Ustekinumab) had planetary income of astir $9.72 billion.
